SEB Asset Management AB Buys New Shares in Neurocrine Biosciences, Inc. $NBIX

Posted by Francis Steltz on Jul 21st, 2026

SEB Asset Management AB bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the 1st quarter, HoldingsChannel.com reports. The fund bought 79,577 shares of the company’s stock, valued at approximately $10,483,000.

Other large investors have also bought and sold shares of the company. Nilsine Partners LLC bought a new position in Neurocrine Biosciences in the 4th quarter valued at $1,197,000. Ruffer LLP bought a new stake in shares of Neurocrine Biosciences during the 4th quarter worth $2,479,000. Nordea Investment Management AB boosted its holdings in shares of Neurocrine Biosciences by 81.3% in the 4th quarter. Nordea Investment Management AB now owns 27,202 shares of the company’s stock worth $3,834,000 after buying an additional 12,195 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in shares of Neurocrine Biosciences by 17,250.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock worth $1,120,000 after buying an additional 7,935 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Neurocrine Biosciences by 785.6% during the fourth quarter. SG Americas Securities LLC now owns 134,530 shares of the company’s stock valued at $19,080,000 after buying an additional 119,339 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Neurocrine Biosciences

In related news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the sale, the director owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. This represents a 30.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the completion of the transaction, the director owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. This represents a 32.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 394,172 shares of company stock valued at $62,221,181. 4.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NBIX. Leerink Partners raised their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Royal Bank Of Canada increased their target price on shares of Neurocrine Biosciences from $183.00 to $195.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Wedbush raised their price target on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Canaccord Genuity Group lifted their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $175.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $192.86.

Get Our Latest Stock Analysis on Neurocrine Biosciences

Neurocrine Biosciences Trading Up 1.2%

Neurocrine Biosciences stock opened at $173.00 on Tuesday. The firm has a 50 day simple moving average of $164.19 and a 200 day simple moving average of $144.02. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $181.18. The firm has a market capitalization of $17.40 billion, a price-to-earnings ratio of 26.66, a P/E/G ratio of 0.68 and a beta of 0.39.

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.